Skip to content
Research Article Open access CC BY 4.0

Pangenotypic Hepatitis C Therapy with Direct Acting Antivirals: A Southern Nigeria Pilot Experience

Abere Sarah, Oyan Boma, Kooffreh-Ada Mbang, Ijoma Uchenna

Asian Journal of Research in Infectious Diseases · pp. 22–32 · Published 6 Aug 2022

10.9734/ajrid/2022/v10i430297

Abstract

Background: Viral hepatitis C (HCV) is a global health challenge affecting at least 3.3% of the world population. Sub-Saharan Africa still battles with under diagnosis,  and poor access to diagnostic facilities occasioned by a lack of manpower/facilities to treat infected persons bringing about an increase in HCV-associated morbidity and mortality.  The goal of this prospective observational study is to assess the efficacy of sofosbuvir/daclatasvir (SOF/DAC) combination as a pangenotypic treatment for hepatitis C without HCV genotype determination in patients with hepatitis C attending the hepatology clinic at the Rivers State University Teaching Hospital (RSUTH). Method: One hundred and fifty (150) HCV RNA positive patients were enrolled into the study. Their sociodermographic factors, clinical and laboratory parameters including pre and post treatment HCV RNA were assessed. Treatment eligible patients received sofosbuvir 400mg and daclatasvir 60/90mg for 12 weeks which was extended to 24 weeks in patients with decompensated liver disease. Treatment success was defined as undetectable HCV RNA 12 weeks after completion of therapy (SVR-12). Results: One hundred and nine (109) of the 150 recruited patients were eligible for treatment. The male to female ratio of the study population was 1.1:1(79, 52.7%):71,49.3%) with a mean age of 47.78±13.39 years. Eighty-six (86,78.9%) of the 109 treated patients had undetectable HCV RNA at SVR-12 and this was most likely to occur in patients with low viremia (OR=2.52, 95%CI=0.985-6.436, p=0.050). Extension of treatment duration played no apparent role in the achievement of SVR-12 (SVR-12=33.3%), however, previously treated HCV patients had a better outcome. Conclusion: Sofosbuvir/ daclatasvir pangenotypic therapy is effective for treatment of HCV patients without genotyping.

Direct acting antivirals Hepatitis C virus pangenotypic sustained virological response-12

References (20)

  1. 1 EASL recommendations on treatment of hepatitis C: Final update of the series☆ [DOI]
  2. 2 Treating viral hepatitis C: efficacy, side effects, and complications [DOI]
  3. 3 Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection [DOI]
  4. 4 Sofosbuvir: A novel treatment option for chronic hepatitis C infection [DOI]
  5. 5 Direct acting anti-hepatitis C virus drugs: Clinical pharmacology and future direction [DOI]
  6. 6 Treatment of hepatitis C virus infection with direct‐acting antiviral agents: 100% cure? [DOI]
  7. 7 Seroprevalence of Hepatitis B Infection in Nigeria: A National Survey [DOI]
  8. 8 Efficacy of Sofosbuvir and Daclatasvir in Patients With Fibrosing Cholestatic Hepatitis C After Liver Transplantation [DOI]
  9. 9 Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension [DOI]
  10. 10 Pangenotypic direct acting antivirals for the treatment of chronic hepatitis C virus infection: A systematic literature review and meta-analysis [DOI]
  11. 11 Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection [DOI]
  12. 12 A Novel Promising Therapeutic Option Against Hepatitis C Virus: An Oral Nucleotide NS5B Polymerase Inhibitor Sofosbuvir [DOI]
  13. 13 Pattern of liver disease admissions in a Nigerian tertiary hospital [DOI]
  14. 14 Specifically targeted antiviral therapy for hepatitis C virus [DOI]
  15. 15 The burden of viral hepatitis in Africa.
  16. 16 Hepatitis C virus infection and its associated factors among prisoners in a Nigerian prison [DOI]
  17. 17 Prevalence of Hepatitis C virus antibody among undergraduates in Ogbomoso, Southwestern Nigeria [DOI]
  18. 18 Pegylated Interferon and Ribavirin Treatment for Hepatitis C Virus Infection [DOI]
  19. 19 Hepatitis C in Adults and Children: A Cross-Sectional Review from a Tertiary Hospital, Northeast Nigeria during the Period 2008-2015 [DOI]
  20. 20 EASL recommendations on treatment of hepatitis C: Final update of the series (2020)

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

55

Page views

0

PDF downloads

15

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.